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Introduction
The prevalence of Type 2 diabetes mellitus (T2DM) is
increasing worldwide, but the rate of increase is partic-
ularly rapid in Asian countries. In the US, the preva-
lence of diagnosed diabetes increased from 2 to 6% in
the 40-year period from 1960 to 2000, approximating a
1% increase per decade.
1 In contrast, the prevalence
of T2DM in China has tripled from 3.2% in 1996
2
to recent estimates of 9.7% in 2010.
3 This pattern is
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Abstract
Background: The First Basal Insulin Evaluation (FINE) Asia study is a
multinational, prospective, observational study of insulin-naı¨ve Type 2 dia-
betes mellitus (T2DM) patients in Asia, uncontrolled (A1c ‡ 8%) on oral
hypoglycemic agents, designed to evaluate the impact of basal insulin
initiation.
Methods: Basal insulin was initiated with or without concomitant oral ther-
apy and doses were adjusted individually. All treatment choices, including
the decision to initiate insulin, were at the physician’s discretion to reﬂect
real-life practice.
Results: Patients (n ¼ 2679) from 11 Asian countries were enrolled (mean
[±SD] duration of diabetes 9.3 ± 6.5 years; weight 68.1 ± 12.7 kg; A1c
9.8 ± 1.6%). After 6 months of basal insulin (NPH insulin, insulin glar-
gine, or insulin detemir), A1c decreased to 7.7 ± 1.4%; 33.7% patients
reached A1c <7%. Fasting blood glucose (FBG) decreased from
11.7 ± 3.6 to 7.2 ± 2.5 mmol⁄L and 36.8% of patients reached FBG
<6.1 mmol⁄L. The mean daily insulin dose prescribed increased marginally
from 0.18 to 0.23 U⁄kg per day at baseline to 0.22–0.24 U⁄kg per day at
Month 6. Mean changes in body weight and reported rates of hypoglyce-
mia were low over the duration of the study.
Conclusions: Initiation of insulin therapy is still being delayed by approxi-
mately 9 years, resulting in many Asian patients developing severe hyper-
glycemia. Initiating insulin treatment with basal insulin was effective and
safe in Asian T2DM patients in a real-world setting, but insulin needs may
differ from those in Western countries.
Keywords: Asia, insulin, Type 2 diabetes mellitus.
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fold increases in the prevalence of T2DM over the past
30 years reported in India, Indonesia, Korea, and
Thailand.
4
In addition to a rapid rate of increase, the diabetes
epidemic in Asia is characterized by a relatively young
onset and low body mass index (BMI). Asian individu-
als show a higher percentage of body fat and greater
abdominal obesity compared with Western patients
with an equivalent BMI.
5,6 The tendency of Asian
patients to develop T2DM at a younger age, and so
suffer longer with diabetes-associated complications
than Western patients,
5 makes the need for effective
management strategies all the more important in order
to minimize the burden of diabetes-associated morbid-
ity and mortality.
Tight glycemic control has been established as the
cornerstone of effective diabetes management in Euro-
pean and US studies,
7–11 as well as in studies of Asian
patients.
12 Based on such data, the International Dia-
betes Federation (IDF) Western Paciﬁc Region has
proposed a preferred target of A1c £ 6.5% for Asian
patients with T2DM.
13,14 The American Diabetes
Association (ADA)⁄European Assocaiton for the
Study of Diabetes (EASD) consensus statement
15 sug-
gests an A1c target of <7% and recommends early
initiation of insulin in patients not meeting A1c tar-
gets. Indeed, it recommends that basal insulin could be
added as soon as possible after the ‘‘failure’’ of diet
and exercise plus metformin (i.e. A1c ‡ 7.0% for 2–
3 months).
15 A recent randomized controlled trial has
demonstrated that prompt addition of basal insulin to
patients with an A1c level of 7–8% on maximal doses
of metformin and sulfonylurea provides clinically rele-
vant improvements in glycemic control compared with
intensiﬁcation of lifestyle factors.
16
However, despite the proven beneﬁts of insulin
therapy and existing guidelines for the initiation of
insulin therapy, evidence suggests that insulin utiliza-
tion and glycemic control remain suboptimal. In the
Hong Kong Diabetes Registry, of 7549 Chinese
patients with T2DM, mean A1c was 7.7 ± 1.8% and
most patients (60.3%) had A1c >7.0% despite the
fact that many were receiving multiple oral hypogly-
cemic agents (OHAs).
17 Moreover, the proportion of
patients with inadequate glycemic control on OHAs
(A1c ‡ 7%) in that study increased with an increas-
ing duration of T2DM, from 23.7% of patients with
diabetes for <5 years to 75.9% of patients a disease
duration of ‡20 years.
17 Similar patterns of inade-
quate therapy intensiﬁcation were reported in the
DiabCare
18,19 study and the International Diabetes
Mellitus Practice Study (IDMPS) registry.
20 These
studies revealed that insulin utilization in Asia has
not changed markedly over the past 10 years, despite
evolving treatment guidelines advocating the initiation
and intensiﬁcation of therapy to reach A1c goals of
<6.5%.
13 The objective of the First Basal Insulin
Evaluation (FINE) Asia study was to provide details
on the real-world initial insulinization of patients
with T2DM across Asia and to determine the tolera-
bility and efﬁcacy of basal insulin regimens in this
region.
Methods
Objectives of the registry
The primary objective of the registry was to collect
real-world information on the initiation of basal insu-
lin in insulin-naı¨ve T2DM patients inadequately con-
trolled on OHAs in Asia.
Registry design
Patients in the present multinational, prospective,
observational study were enrolled from 195 centers⁄
sites across 11 different Asian countries (Bangladesh,
China, Hong Kong, India, Indonesia, Korea, Pakistan,
Singapore, Taiwan, Thailand, and Vietnam) from 2006
to 2008.
Patients
Patients were aged 20 years or older, had inade-
quately controlled T2DM (A1c ‡ 8%) on OHAs, and
required the initiation of a basal insulin based on the
judgment of their treating physician.
15 Patients were
ineligible for inclusion in the study if they had been
prescribed insulin before the registry period (except
for acute rescue insulin therapy) or had been pre-
scribed premixed insulin at the start of the registry
period. Women who were either pregnant or of child-
bearing age and not using a reliable contraceptive for
the duration of the study were also excluded from the
registry.
Study treatment and assessments
Basal insulin was initiated with or without concomi-
tant OHAs. No speciﬁc protocol was recommended as
to the type of basal insulin or OHAs administered,
which were prescribed at the discretion of the treating
physician. Basal insulin doses were adjusted individu-
ally based on the recommendations of the locally
approved package inserts. The treatment duration was
6 months.
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and at 3 and 6 months. The registry involved three
main visits, namely at inclusion and at Months 3
(±7 days) and 6 (±7 days), in addition to standard
clinical visits as deemed appropriate by the patient and
physician. Each visit included standard physical exam-
inations (including body weight and blood pres-
sure), assessment of A1c, fasting blood glucose (FBG)
and self-monitoring blood glucose (SMBG) proﬁles,
adverse drug reactions (ADRs), and hypoglycemic epi-
sodes. Patients were recommended to perform SMBG
using their own glucose monitors as per their usual
practice. In addition, SMBG was recommended when
mild-to-moderate hypoglycemic events occurred. Physi-
cian and patient assessments of treatment satisfaction
were collected at study end based on a four-point scale
of satisfaction rated as ‘‘not good’’, ‘‘moderate’’,
‘‘good’’, and ‘‘very good’’.
Primary and secondary endpoints
The primary efﬁcacy endpoint was the change in A1c
from baseline to Months 3 and 6 after insulin initia-
tion. Secondary and other efﬁcacy endpoints included
the change in FBG from baseline to Months 3 and 6
after insulin initiation, response rates (the percentage of
patients reaching A1c <7% or achieving the treatment
target), mean insulin doses, number of severe hypogly-
cemic events, and treatment satisfaction.
Safety was evaluated using the ADRs reported dur-
ing the registry, including all non-serious ADRs (espe-
cially hypoglycemic events), serious ADRs, overdoses,
and changes in clinical and⁄or laboratory data. Severe
hypoglycemia was deﬁned as blood glucose (BG)
<3.9 mmol⁄L and requiring assistance. Mild to mod-
erate hypoglycemia was deﬁned as episodes that were
suggestive of hypoglycemia with no need for external
assistance, with BG <3.9 mmol⁄L but asymptomatic,
or symptomatic hypoglycemia with or without a blood
glucose measurement.
Statistical analysis
Statistical analyses were based on patients with A1c
data at both baseline and 6 months. All data were
entered into a single database by double data entry
and were validated in terms of limits, coding, missing
data, and consistency checks. Any missing or incom-
plete data were queried unless speciﬁed as unknown.
All data were analyzed in an exploratory manner using
sas Version 8.2 (SAS Institute, Cary, NC, USA).
Summary statistics (mean, median, range, and SD for
continuous variables, and the number and percentage
for categorical variables) were determined. Student’s
paired t-test was used to compare parameters before
and after the treatment period. Qualitative variables
were compared using Fisher’s exact probability test or
Chi-squared tests. All statistical tests were performed
using two-tailed tests at a 5% level of signiﬁcance or
with adjustment if appropriate. A least squares multi-
variate procedure was used to adjust outcome variables
with signiﬁcant baseline differences across treatment
groups.
Results
Patient characteristics
Across 11 Asian countries, a total of 3024 patients were
screened, of whom 103 were deemed ineligible for the
present study (Fig. 1). A total of 2921 patients (1452
men and 1469 women, with a mean [±SD] age of
56.4 ± 11.2 years, T2DM duration of 9.3 ± 6.5 years,
duration of OHA therapy of 8.7 ± 6.4 years, A1c lev-
els of 9.8 ± 1.6%, and FBG of 11.7 ± 3.6 mmol⁄L)
were included at baseline. Overall, 2808 and 2751
patients attended visits at Months 3 and 6, respectively.
Reasons for discontinuation are shown in Fig. 1. One
hundred and thirty-one patients treated with insulin
glargine (baseline–Month 3, n ¼ 82; Month 3–6, n =
49), 33 treated with NPH insulin (n ¼ 15 and 18,
respectively), and six treated with insulin detemir
(n ¼ 4 and 2, respectively) were lost to follow-up.
The baseline characteristics and clinical characteris-
tics of the total evaluable population (patients who
had baseline and Month 6 A1c data; n ¼ 2679) are
given in Tables 1 and 2, respectively. At the screening
visit, 2196 patients (75.2%; evaluable n ¼ 2016) were
prescribed insulin glargine, 637 (21.8%; evaluable
n ¼ 589) were prescribed NPH insulin, and 75 (2.6%;
evaluable n ¼ 61) were prescribed insulin detemir.
Thirteen patients (0.5%; evaluable n ¼ 13) started
another type of insulin. The study population repre-
sents a broad range of patients with T2DM and the
general characteristics were, on the whole, comparable
between the countries involved. However, there were
some differences in patient characteristics among
groups of patients according to insulin prescribed,
including diabetes duration, duration of OHA treat-
ment, and FBG levels (Table 2), but age and BMI
were comparable. As indicated in Table 3, 80.8% of
patients (n = 2360) were using combination OHA
therapy before the baseline visit; this percentage
decreased at the time of insulin initiation (n = 2012;
68.9%). The mean (±SD) doses of insulin at baseline
were 0.20 ± 0.09 U⁄kg for insulin glargine, 0.18 ±
0.11 U⁄kg for NPH insulin and 0.23 ± 0.10 U⁄kg for
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stable at Months 3 and 6 (Table 3).
Glycemic control
In the total study population at Month 6, A1c was sig-
niﬁcantly lower than at baseline (P < 0.0001; Fig. 2a).
At similar daily insulin doses, baseline-adjusted A1c
levels were reduced by 2.2% with insulin glargine,
1.9% with NPH insulin, and 0.8% with insulin det-
emir, whereas the unadjusted A1c reductions were
2.1%, 2.1%, and 1.1%, respectively. The overall pro-
portion of patients who achieved an A1c target <7%
at Month 6 was 33.7% (35.2% with insulin glargine,
30.7% with NPH insulin, and 9.8% with insulin
detemir). Similarly, the mean FBG level in the total
population was signiﬁcantly lower at Month 6 com-
pared with baseline (all P < 0.0001; Fig. 2b), as were
those with insulin glargine, NPH insulin, and insulin
detemir. Unadjusted reductions in FBG for insulin
glargine, NPH insulin, and insulin detemir were 4.5,
4.5, and 3.6 mmol⁄L, respectively. An FBG target of
<6.1 mmol⁄L at Month 6 was achieved by 36.8% of
total patients (39.5% with insulin glargine, 29.7% with
NPH insulin, and 23.0% with insulin detemir).
Body weight
Overall, the change in body weight was minimal (mean
change )0.06 kg). For patients receiving insulin
glargine, NPH insulin, and insulin detemir, baseline-
adjusted changes in body weight were )0.04, )0.13,
Figure 1 Patient distribution. *Includes patients that missed the visit at Month 3.
Patients with follow-up visits at Months 3 and 6. OHA,
oral hypoglycemic agent; FBG, fasting blood glucose.
S.-T. TSAI et al. First basal insulinization in Asians
ª 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd 211
A
S
I
A
T
R
A
C
Kand )0.01 kg, respectively; unadjusted changes were
)0.02, )0.21, and )0.01 kg, respectively. Changes in
body weight in those who achieved A1c <7%
(n ¼ 901) were not signiﬁcant, with a mean change in
weight of 0.06 ± 2.68 kg for a mean change in A1c of
2.85 ± 1.40%.
Hypoglycemia and ADRs
A total of 389 patients (14.5%) reported ADRs,
including 233 (11.6%) with insulin glargine, 141
(24.9%) with NPH insulin, 12 (19.7%) with insulin
detemir, and three (23.1%) with other insulins. Most
events were episodes of hypoglycemia, with only ﬁve
ADRs other than hypoglycemia reported. The inci-
dence of any hypoglycemic event in the total study
population over 6 months of treatment was 0.287
events⁄patient-year (mild-to-moderate 0.280 events⁄
patient-year; severe 0.009 events⁄patient-year). Accord-
ing to insulin treatment received, the incidence (events⁄
patient-year) of mild-to-moderate and severe hypogly-
cemia at Month 6 were 0.224 and 0.003, respectively,
for those on insulin glargine; 0.458 and 0.031, respec-
tively, for those on NPH insulin; and 0.361 and 0.000,
respectively, for those on insulin detemir.
Of the ﬁve ADRs other than hypoglycemia reported,
all were mild in severity. Among patients receiving
insulin glargine, one experienced injection site numb-
ness, which resolved after changing injection site, and
a second patient had low-grade fever that subsided on
discontinuation. In those receiving NPH insulin, one
patient experienced edema, which disappeared on dis-
continuation, and a second patient had an injection
site skin reaction, also resulting in discontinuation.
One patient receiving insulin detemir reported dull
pain, which recovered following a change in dose.
Treatment satisfaction
Treatment satisfaction was high for both physicians
and patients. A total of 2661 responses from a maxi-
mum total of 2679 (response rate 99.3%) were
recorded, with most physicians rating insulin treatment
as either good or very good (34.2% and 37.4%, respec-
tively). Across the different insulins, the proportion
of physicians reporting ‘‘good’’ or ‘‘very good’’ was
33.9% and 42.5%, respectively, for insulin glargine;
36.9% and 21.4%, respectively, for NPH insulin; and
22.9% and 19.7%, respectively, for insulin detemir.
Table 2 Clinical characteristics at baseline
Glargine
(n = 2016)
NPH insulin
(n = 589)
Insulin detemir
(n = 61)
Total
(n = 2679)
Duration of diabetes (years) 9.5 ± 6.5*
 8.2 ± 6.0 10.9 ± 7.2 9.3 ± 6.5
Duration of OHA treatment (years) 8.9 ± 6.3*
 7.7 ± 5.9
 10.6 ± 7.1 8.7 ± 6.3
A1c (%) 9.7 ± 1.5* 10.1 ± 1.9 10.2 ± 1.7 9.8 ± 1.6
FBG (mmol⁄L) 11.6 ± 3.5 12.0 ± 3.6 12.6 ± 3.2 11.7 ± 3.5
SBP (mmHg) 134.1 ± 17.1* 132.5 ± 17.3 132.4 ± 16.5 133.8 ± 17.2
DBP (mmHg) 81.3 ± 10.5*
 79.2 ± 10.1 77.0 ± 10.3 80.8 ± 10.4
Diagnosed hypertension 1342 (66.9) 358 (61.0) 44 (72.1) 1754 (65.8)
Coronary artery disease 293 (15.5) 64 (11.4) 11 (18.3) 370 (14.6)
Stroke 84 (4.4) 29 (5.0) 1 (1.7) 114 (4.4)
Data are presented as the mean ± SD or the number of subjects in each group with percentages given in parentheses, as appropriate. Note,
the percentages were calculated based on the number of patients with evaluable data rather than the total eligible population. *P < 0.0001
compared with NPH insulin;
P < 0.0001 compared with insulin detemir.
OHA, oral hypoglycemic agent; FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 1 Patient characteristics at baseline
Parameter
Glargine
(n = 2016)
NPH
insulin
(n = 589)
Insulin
detemir
(n = 61)
Total
(n = 2679)
Gender
No.
men (%)
1041 (51.6) 258 (43.8) 28 (45.9) 1334 (49.8)
No.
women (%)
975 (48.4) 331 (56.2) 33 (54.1) 1345 (50.2)
Age (years) 56.6 ± 11.2 55.5 ± 11.2 56.1 ± 9.7 56.4 ± 11.2
Weight (kg) 69.0 ± 12.6* 65.1 ± 12.0 67.9 ± 13.6 68.1 ± 12.7
Mean BMI
(kg⁄m
2)
26.3 ± 4.9* 25.3 ± 4.1 26.0 ± 4.6 26.1 ± 4.7
BMI
>23 kg⁄m
2 1513 (77.2) 414 (70.8) 46 (75.4) 1983 (75.7)
>25 kg⁄m
2 1104 (56.4) 289 (49.4) 37 (60.7) 1435 (54.8)
Data are presented as the mean ± SD or the number of subjects in
each group with percentages given in parentheses, as appropriate.
Note, the percentages were calculated based on the number of
patients with evaluable data rather than the total eligible population.
*P < 0.0001 compared with NPH insulin.
BMI, body mass index.
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tion question from a maximum total of 2679 (response
rate 99.2%). The overall percentage of patients that
rated insulin treatment as either ‘‘good’’ or ‘‘very
good’’ was 41.3% and 35.6%, respectively. For indi-
vidual treatments, the corresponding ﬁgures were
40.0% and 41.3% for insulin glargine; 47.6% and
20.7% for NPH insulin; and 27.9% and 23.0% for
insulin detemir.
Discussion
The results of the present prospective, observational,
registry-based study showed that initiation of basal
insulin in Asian patients with long-standing T2DM
failing OHA therapy provided clinically important
improvements in glycemic control. However, the pres-
ent study also reveals that despite the clinical beneﬁts
and the recommendations of international treatment
guidelines,
13–15 the initiation of insulin therapy in Asia
is still being delayed for too long, resulting in many
patients developing severe hyperglycemia.
Our study population comprised patients with poorly
controlled T2DM, with a mean A1c level of 9.8%, a
mean duration of diabetes of 9.3 ± 6.5 years, and a
mean duration of OHA therapy of 8.7 ± 6.3 years
before insulinization. Approximately one-third of
patients had an A1c level >10%. This conﬁrms that
treatment intensiﬁcation and the initiation of insulin
therapy is still being delayed in Asian patients, irrespec-
tive of international and regional guidelines.
13,14 This
ﬁnding is not unique to Asian countries. The Cardio-
vascular Risk Evaluation in People with Type 2 Dia-
betes on Insulin Therapy (CREDIT) registry of 3031
patients who recently started insulin therapy in North-
ern America, Europe, and Asia found that the mean
duration of T2DM was 11 years and the mean A1c
level at baseline was 9.5%.
21
Initiation of basal insulin in the present study resulted
in a statistically and clinically signiﬁcant reduction in
mean A1c levels from 9.8 to 7.7% over 6 months. As a
result, one-third of patients reached the ADA⁄EASD
consensus A1c target of <7%. The mean basal insulin
dose of 0.22–0.24 U⁄kg required to achieve this 2%
reduction in A1c was low compared with studies in
Western populations. For example, in the Treat-to-
Target study of North American patients with T2DM,
the mean change in A1c was approximately )1.6% over
Table 3 Changes in oral antihyperglycemic agents and insulin during the study
Prior therapy Initial visit
Current therapy
Month 3 Month 6
None 0 (0) 50 (1.7) N⁄AN ⁄A
Monotherapy 561 (19.2) 859 (29.4) N⁄AN ⁄A
Combination* 2360 (80.8) 2012 (68.9) N⁄AN ⁄A
2 1503 (51.5) 1488 (50.9) N⁄AN ⁄A
3 765 (26.2) 484 (16.6) N⁄AN ⁄A
4 85 (2.9) 40 (1.4) N⁄AN ⁄A
5 7 (0.2) 0 (0) N⁄AN ⁄A
Type
Sulfonylureas 2507 (85.8) 2135 (73.1) 1982 (70.6) 1848 (67.2)
Biguanides 2259 (77.3) 1979 (67.8) 1846 (65.7) 1724 (62.7)
Thiazolidinediones 777 (26.6) 639 (21.9) 574 (20.4) 558 (20.3)
a-Glucosidase inhibitors 501 (17.2) 474 (16.2) 434 (15.5) 443 (16.1)
Meglitinides 170 (5.8) 216 (7.4) 219 (7.8) 258 (9.4)
Others 24 (0.8) 4 (0.1) 4 (0.1) 10 (0.4)
None 0 (0) 50 (1.7) 80 (2.9) 83 (3.0)
Insulin glargine 0 (0) 2196 (75.2) 2038 (72.6) 1952 (71.0)
NPH insulin 0 (0) 637 (21.8) 587 (20.9) 553 (20.10)
Insulin detemir 0 (0) 75 (2.6) 68 (2.4) 63 (2.3)
Other insulin 0 (0) 13 (0.5) 62 (2.2) 101 (3.7)
No insulin 53 (1.9) 82 (3.0)
Mean (±SD) insulin dose (U⁄kg)
Insulin glargine 0.20 ± 0.09 0.21 ± 0.10 0.22 ± 0.10
NPH insulin 0.18 ± 0.11 0.21 ± 0.13 0.23 ± 0.14
Insulin detemir 0.23 ± 0.10 0.23 ± 0.09 0.24 ± 0.10
Data are presented as the mean ± SD or the number of subjects in each group with percentages given in parentheses, as appropriate.
*Numbers refer to the number of drugs (listed below in ‘‘Type’’) used in combination by patients.
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insulin glargine and 0.42 U⁄kg (41.8 IU) for NPH
insulin.
22 Meanwhile, in a study of European patients,
the mean change in A1c was )0.96% with bedtime
insulin glargine compared with )0.84% with NPH
insulin over 6 months, with insulin doses reaching 39
and 37 IU at endpoint, respectively.
23 The lower insu-
lin doses in the present study may reﬂect the generally
lower BMI of Asian compared with Western T2DM
patients. The mean BMI in the present study was
26.1 kg⁄m
2, compared with approximately 28 kg⁄m
2 in
the European study
23 and 32 kg⁄m
2 in the Treat-to
Target study of North American patients.
22 This
observation is consistent with a large population-based
study of 3071 Asians and 129 116 non-Hispanic
Whites in the US.
6
Thus, Asian patients with T2DM may have lower
insulin needs compared with non-Asian populations.
Nevertheless, only one-third of patients treated with
basal insulin glargine in the present study reached an
A1c <7.0%. Patterns of insulin titration observed in the
present study may be reﬂective of a cautious approach
to insulin titration among physicians in Asia. Trials of
insulin in Asian subjects report using a conservative
titration goal relative to comparative trials in Western
populations owing to a perceived increased risk of hypo-
glycemia in Asian patients
24 who are leaner than their
Western counterparts. Rates of hypoglycemia in the
present study were low and it is tempting to speculate
that more aggressive dose titration, as recommended by
the IDF Western Paciﬁc Region,
13,14 may have resulted
in more patients achieving the <7.0% A1c target.
It should be noted that observational registry-based
studies, such as the present study, have a number of
advantages and disadvantages compared with random-
ized controlled trials. The major advantages of a regis-
try are the potential for larger-scale trials with greater
numbers of patients and the ability to monitor therapy
under ‘‘real-life’’ conditions that may better reﬂect
how the treatment is used in practice. However, regis-
try studies are not randomized and the characteristics
of patients receiving the different treatment modalities
may not be consistent; there may also be some differ-
ences between the use of insulins within each country
or by each physician. Thus, conclusions about the
comparative efﬁcacy of NPH insulin, insulin glargine,
and insulin detemir in an Asian population cannot be
drawn from the present observational study.
Indeed, there were marked differences in the number
of patients who were prescribed each of the insulins in
the present study (n = 2196, 637, and 75 for insulin
glargine, NPH insulin, and insulin detemir, respec-
tively). This may reﬂect the availability or awareness of
the different insulins among some of the countries
included here; for example, insulin detemir was not
available in China and Vietnam at the time of the study
and was a new addition to clinical practice in many of
the other countries. Physicians are less likely to be
familiar with the use of insulin detemir than that of
NPH insulin and insulin glargine. In particular, insulin
detemir has the option for once- or twice-daily dosing
and, because some patients require twice-daily treat-
ment to achieve optimal beneﬁt, there may have been a
greater risk of suboptimal titration with this agent.
(a)
(b)
Figure 2 (a) A1c and (b) fasting blood glucose levels at baseline
(j) and Months 3 ( ) and 6 (h) adjusted for baseline. *Includes 13
patients treated with insulin listed as starting another type of
insulin. Data are mean values.
P < 0.0001 compared with baseline.
D, change from baseline.
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receiving the different insulins and was longest in those
receiving insulin detemir, which may have inﬂuenced
efﬁcacy outcomes. Variations in baseline A1c levels in
patients receiving the different insulins may also have
affected the efﬁcacy outcomes, and this is reﬂected in
the differences between unadjusted and adjusted A1c
and FBG changes reported in the present study.
In general, patients with higher initial A1c levels are
known to respond more readily to insulin than those
with initial A1c levels closer to target.
It should also be noted that a threshold of
A1c ‡ 8% was selected for the present registry study
to include only patients who would be candidates for
insulin therapy, whereas people with an A1c of 7–8%
are more likely to achieve their therapeutic goal with
current therapy as an initial step, before adding a new
treatment such as insulin.
15 Accordingly, the character-
istics of the patients included in the present study,
being an incomplete cross-section of patients with
T2DM, do not fully reﬂect the heterogeneity of the
patient population. Nevertheless, we were able to
include a large number of patients with unacceptably
high A1c levels who should be considered as candi-
dates for treatment modiﬁcation and intensiﬁcation.
15
In addition, the FINE Asia study analysis did not
account for variations in the methods used to measure
A1c and relied on accurate physician reporting of A1c
levels across the countries involved. Furthermore, initi-
ation of the appropriate insulin dose was determined
by country-speciﬁc prescribing information, which
may also have led to procedural variation across the
countries in question. Although these are potential
limitations to the study analysis, they are reﬂective of
‘‘real-world’’ clinical practice, which was a key aim of
the present study.
It is important to consider the results of the present
study in light of the limitations described above. Yet,
the data presented here support the ﬁndings from prior
registry studies
13,14 that insulin therapy is underused
and glycemic control is suboptimal in a large propor-
tion of patients with T2DM in Asia. The FINE Asia
study investigated basal insulin initiation, which repre-
sents only one of several options for patients with
T2DM suboptimally controlled with oral agents. Basal
insulin therapies studied here were selected at the dis-
cretion of the treating physician alone. Thus, our sur-
vey conﬁrms, in a real-world setting, the ﬁndings from
randomized controlled trials that the initiation of basal
insulin is an effective and well-tolerated treatment
option in Asian patients with T2DM failing to meet
targets with OHA therapy. The study also indicates
that Asian patients may have lower insulin needs,
possibly related to a lower mean BMI than compara-
ble Western populations. However, more aggressive
dose titration may enable more patients to achieve
treatment targets and so limit the burden of diabetes
associated complications among Asian populations.
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